Abstract 1100 Targeting tubulin with small molecule anti-cancer inhibitors

The National Cancer Institute reports that cancer will claim the lives of an estimated 611,720 people in the United States in 2024, and an estimated 2,000,000 more people will be newly diagnosed. Common therapies include chemotherapy, immunotherapy, and small molecule drugs. As cancer involves uncontrolled cell growth and tubulin plays a crucial role in cell division, interest in tubulin inhibitors has been at the forefront of potential therapies. Many tubulin inhibitors are large molecules, have high toxicity issues, suffer from low solubility, lack multi-cancer efficacy, and become ineffective due to cancer resistance.